Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1658 results about "Capsid" patented technology

A capsid is the protein shell of a virus. It consists of several oligomeric structural subunits made of protein called protomers. The observable 3-dimensional morphological subunits, which may or may not correspond to individual proteins, are called capsomeres. The capsid encloses the genetic material of the virus.

Fitness maturation of engineered AAV capsid STAC-102

This application relates to engineering AAV capsids, for example, STAC-102. In some embodiments, the engineered AAV capsids mediate delivery to the central nervous system.
Owner:SANGAMO THERAPEUTICS INC

Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency

PCT designated stage expiredWO2024229167A1Organic active ingredientsNervous disorderSTXBP1Capsid
The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of STXBP1 proteins via delivery using an adeno-associated virus (AAV) capsid variant. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having STXBP1 encephalopathy, or another STXBP1-related disorder.
Owner:VOYAGER THERAPEUTICS INC

Compositions and methods for the treatment of disorders related to CDKL5 deficiency

PCT designated stage expiredWO2024229163A1Nervous disorderPeptide/protein ingredientsCDKL5Capsid
The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of CDKL5 proteins via delivery using an adeno-associated virus (AAV) capsid variant. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having CDD, or another CDKL5-related disorder.
Owner:VOYAGER THERAPEUTICS INC

Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency

PCT designated stage expiredWO2024229161A1Polypeptide with localisation/targeting motifNervous disorderAdenoassociated virusGlucosylceramidase beta
The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of GBA1 protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, in the treatment of subjects who have, have been diagnosed with, or are at risk of having a GBA1-related disorder, e.g., Parkinson's Disease (PD), Gaucher Disease (GD), Parkinson's Disease Dementia (PDD), Dementia with Lewy Bodies (DLB), or Lewy Body Dementia (LBD).
Owner:VOYAGER THERAPEUTICS INC

Compositions and methods for the treatment of disorders related to ataxin-2

The disclosure relates to compositions and methods for modulating, e.g., reducing or eliminating, the expression of ATXN2 via delivery of a modulatory polynucleotide using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having, spinocerebellar ataxia type 2 or another ATXN2-related disorder.
Owner:VOYAGER THERAPEUTICS INC

Compositions and methods for the treatment of disorders related to frataxin deficiency

PCT designated stage expiredWO2024229125A2Organic active ingredientsVectorsFriedreichs ataxiaFrataxin
The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of frataxin protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, in the treatment of subjects who have, have been diagnosed with, or suspected of having a disorder associated with frataxin (FXN) deficiency, e.g., Friedreich's Ataxia.
Owner:VOYAGER THERAPEUTICS INC

Adeno-associated virus virions with variant capsid and uses thereof

The invention provides an adeno-associated virus virion with a variant capsid and application of the adeno-associated virus virion. Specifically, the invention provides an adeno-associated virus capsid protein variant, a recombinant AAV virus particle containing the capsid protein, a preparation method of the recombinant AAV virus particle and application of the recombinant AAV virus particle in disease treatment and prevention.
Owner:LANGXIN QISHENG (SUZHOU) BIOPHARMACEUTICAL CO LTD

Dosing regimen of capsid inhibitor

The present disclosure relates to dosing regimens of an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.
Owner:GILEAD SCIENCES INC

High-pathogenicity porcine reproductive and respiratory syndrome virus mRNA vaccine composition and application thereof

The invention discloses a high-pathogenicity porcine reproductive and respiratory syndrome virus mRNA vaccine composition and application thereof. The vaccine composition is selected from any one of the following combinations: (1) an mRNA vaccine composition consisting of a PRRSV GP3 mRNA (messenger ribonucleic acid), a PRRSV GP4 mRNA (messenger ribonucleic acid) and a PRRSV GP5 mRNA (messenger ribonucleic acid); or (2) an mRNA vaccine composition consisting of a PRRSV GP5 mRNA, a PRRSV membrane protein (M) mRNA and a PRRSV nucleocapsid protein (N) mRNA. According to the invention, a high-pathogenicity PRRSV JX-A1 strain is used as a template, and mRNAs capable of synthesizing a plurality of fusion proteins GP345, GP5M and GP5MN and single structural proteins GP3, GP4, GP5, M and N are respectively constructed. After liposome encapsulation, mice are inoculated for immunological evaluation, and results show that humoral immunity and cellular immunity levels of a single mRNA-LNPs mixed group are higher than those of recombinant mRNA-LNPs, and GP5 + M + N and GP3 + 4 + 5 have relatively best effects. The invention provides a new technical means for preventing PRRSV (Porcine Reproductive and Respiratory Syndrome Virus).
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Short peptide composition for inhibiting inclusion body formation and promoting self-assembly of Gag-Like protein nanoparticles

The invention discloses an oligopeptide composition for inhibiting inclusion body formation and promoting Gag-Like protein nanoparticle self-assembly, the oligopeptide composition comprises a C-terminal oligopeptide and an N-terminal oligopeptide, the amino acid sequence of the N-terminal oligopeptide is as shown in SEQ ID NO: 1, and the amino acid sequence of the C-terminal oligopeptide is as shown in SEQ ID NO: 2. The oligopeptide composition can effectively avoid formation of a prokaryotic expression protein inclusion body and / or promote dissolution of prokaryotic expression protein, the oligopeptide composition is further utilized to be combined with HIV-1p24 and human endogenous retrovirus K capsid protein CA, nanoparticles are prepared respectively, and the oligopeptide composition can be used as a carrier for antigen surface display or drug transportation. The nanoparticles formed by the HIV-1 capsid protein p24 and the human HERV K CA have cavities which are obviously larger than those of ferritin, so that the nanoparticles have higher loading capacity; as an antigen display platform, the antibody also has good stability and wide applicability.
Owner:SUN YAT SEN UNIV

Nanometer antibody and application thereof

The invention provides a nano antibody and application thereof, a variable region in an amino acid sequence of the nano antibody comprises a complementarity determining region CDR and a framework region FR, the complementarity determining region CDR comprises a complementarity determining region CDR1, a complementarity determining region CDR2 and a complementarity determining region CDR3, the CDR3 is RWPDXY family, and binding sites of the CDR3 and AAV capsid are W99, D101 and Y103. The nano antibody provided by the invention has very high affinity and activity, and can specifically recognize and combine various serotypes of AAV, and an adsorbent prepared from the nano antibody has very strong adsorption capacity on AAV, can be applied to AAV affinity chromatography, and is beneficial to industrial application of an AAV affinity chromatography column. In addition, the method can also be applied to the field of AAV detection, and can detect empty capsid and virions together.
Owner:CROWN MEDICAL TECH DALIAN CO LTD

Method for inducing an immune response

PCT designated stage expiredWO2024228149A2Dispersion deliveryViral antigen ingredientsReplication competent virusVirus antigen
The present invention relates to methods for inducing an immune response in a subject, the method comprising administering orally to the subject an immunogenic composition comprising non-replicating virus antigen. In one example, an immunogenic composition is administered via the oral route to a pig, wherein the immunogenic composition comprises a recombinant virus capsid protein capable of forming a virus-like particle. This allows to simply induce an immune response in the pigs, while simultaneously reducing the propensity for adverse reactions, eliminating the risk of injection site reactions, avoiding pain, and putting less stress on the animals.
Owner:BOEHRINGER INGELHEIM VETMEDICA GMBH

Renal pelvic injection for drug delivery to the kidney

Methods are disclosed for delivering a composition comprising an adeno-associated virus (AAV) to one or more kidney cell types in a subject with or without immunity against AAV, including locally delivering to the kidney of the subject an adeno-associated virus (AAV) comprising a genome and an AAV capsid protein via renal pelvic injection, wherein the renal pelvic injection comprises direct renal pelvic injection or retrograde transureteral renal pelvic injection. Methods are also disclosed for treating a kidney disorder in a subject with or without immunity against AAV, comprising locally delivering to the kidney of the subject via renal pelvic injection, including direct renal pelvic injection and retrograde transureteral renal pelvic injection, an adeno-associated virus (AAV) comprising a genome and an AAV capsid protein, wherein the genome encodes a therapeutic agent that treats the kidney disorder in the subject. The AAV can be AAVKP1, AAVKP2, AAVKP3, AAVDJ, AAV2G9, AAV2.7m8, AAV3, AAVLK03, or AAVShH10.
Owner:OREGON HEALTH & SCI UNIV

Capsid protein mutant capable of improving infection ability of AAV to eye tissues and application of capsid protein mutant

ActiveCN119080889AImprove infection abilitySenses disorderGenetic material ingredientsDiseaseRetinal
The invention belongs to the technical field of biology, and discloses a capsid protein mutant capable of improving the infection ability of AAV to eye tissues and application of the capsid protein mutant. AAVRFDGTERAA and RQYSDAVRAE are inserted into amino acid at the 587 site and amino acid at the 588 site, which are equivalent to that of wild type AAV2 virus capsid protein, so that capsid protein mutants AAV2-NE01 and AAV2-NE02 are obtained. The virus yield of AAV2-NE01 and AAV2-NE02 is 1.96 times and 1.20 times that of AAV2-WT, after intravitreal injection, cells and trabecular meshwork areas of NHP retina GCL, INL to ONL can be well infected, the infection positive rate is high, the fluorescence intensity is high, the penetrating power to the retina is high, and visual cell nucleuses and inner segments can be infected. The AAV vector has a good application prospect and is expected to be developed into the AAV vector for treating eye diseases.
Owner:GUANGZHOU YIMAGENE TECHNOLOGY CO LTD

Mutant AAV with central nervous system targeting motifs and compositions containing same

Provided herein are compositions including brain, brain microvascular endothelial cell-targeting peptides and / or blood-brain barrier crossing (BBB) tissue-targeting peptides linked thereto or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn – n-mer – Xm. Compositions providing such conjugates, targeting peptides, or recombinant vectors having an engineered capsid or envelope protein are provided as are uses thereof.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Preparation method of virus-like particles for displaying scFv antibody as well as product and application of virus-like particles

PendingCN119874846ASsRNA viruses negative-senseVirus peptidesScFv AntibodiesCapsid
The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method of viroid particles displaying scFv antibodies, a product of the viroid particles and application of the viroid particles. The preparation method provided by the invention comprises the following steps: constructing a specific targeting recombinant plasmid, wherein the specific targeting recombinant plasmid is obtained by connecting a vector for expressing virus capsid protein and a coding gene for expressing an scFv antibody display structure through homologous recombination. The vector for expressing the virus capsid protein comprises a coding gene of VSV-G signal peptide, a transmembrane region and an intracellular region, and is as shown in SEQ ID NO. 2. And the coding gene for expressing the scFv antibody display structure is shown as SEQ ID NO. 3-5. According to the preparation method disclosed by the invention, the virus-like particles of which the capsid is a modular component of a specific targeting immune cell are constructed based on a lentivirus system, and 50-90% of infection efficiency can be realized in the immune cell.
Owner:FUBIO (SUZHOU) BIOMEDICAL TECH CO LTD

Lysing bacteriophage for preventing and controlling vibrio in aquaculture environment

The invention discloses a lytic bacteriophage for preventing and controlling vibrio in an aquaculture environment. The bacteriophage vBValMR42H belongs to a muscle tail bacteriophage and is insensitive to chloroform, the capsid of the bacteriophage vBValMR42H is free of lipid substances, and the preservation number is GDMCC No: 67434-B1. The bacteriophage has the characteristics of high adsorption speed, short incubation period and high cracking amount, keeps high activity in a wide range of temperature (4-55 DEG C) and pH (2-11), and has strong environmental adaptability. Genome analysis shows that the bacteriophage does not contain virulence factors, antibiotic resistance genes and lyogen related genes, and is high in biological safety. Physical development analysis shows that the method can be divided into a new genus. The bacteriophage R42H has the advantages of high splitting efficiency, good environmental stability, strong specificity, gene safety and the like, and can be used as an ideal biological prevention and control agent for preventing and controlling vibrio alginolyticus diseases in aquaculture.
Owner:SHENZHEN UNIV

Construction and application of a modified AAV-8 serotype targeting various retinal layers

The present invention belongs to the field of genetic engineering and biotechnology, and relates to the screening, construction and application of a modified type of AAV-8 serotype for gene targeting and expression. The modified type of the AAV-8 serotype of the present invention inserts 10 amino acid sequences between the 590th amino acid and the 591st amino acid of the AAV-8 serotype capsid protein sequence as shown in SEQ ID NO.2, wherein the 3rd to 9th amino acids are amino acid sequences obtained by screening. The modified serotype of the present invention targets each layer of the retina, and the fluorescence effect after infection is stronger, and it can be clearly and intuitively observed that the exogenous gene can be efficiently expressed in each layer of the retina of the targeted tissue, including the retinal ganglion cell layer, the inner nuclear layer, the outer nuclear layer, the photoreceptor cell layer and the retinal pigment epithelial cell layer, and has better and more targeted tissue expression than the wild-type serotype when the same amount of virus is used.
Owner:SHANGHAI OPHTHAL-BRIGHT BIOMEDICINE TECH

Tomato disease-resistant gene mutant, and use thereof in prevention and treatment of tobrfv

PCT designated stageWO2026061116A1Plant peptidesFermentationDiseaseArginine
The present invention belongs to the technical field of biological prevention and treatment for viral diseases. Disclosed in the present invention are a tomato disease-resistant gene mutant, and the use thereof in the prevention and treatment of ToBRFV. It is found in the present invention that mutating the nucleotide at position 1927 of the coding region sequence of tomato Tm-22 gene from G to A, or mutating the amino acid at position 643 of the LRR domain of a protein that is encoded by tomato Tm-22 gene from glycine to arginine can remarkably reduce the accumulation level of ToBRFV capsid protein (CP). The gene (named Tm-22-Mut5) can serve as a novel ToBRFV resistant gene, and also retains the resistance to TMV, ToMV and ToMMV. The Tm-22-Mut5 and a pre-screened Tm-22-Mut3-1 mutant (tyrosine at position 767 of the LRR domain thereof is mutated to phenylalanine) undergo combinatorial mutagenesis to obtain a mutant Tm-22-Mut6. Analysis shows that the Tm-22-Mut6 can remarkably reduce the accumulation level of the ToBRFV capsid protein. Compared with the pFGCTm-22-Mut3-1 mutant obtained by screening in the previous research and the newly obtained mutant Tm-22-Mut5, the Tm-22-Mut6 has further improved resistance to ToBRFV.
Owner:SHANDONG AGRICULTURAL UNIVERSITY

Method for preparing human metapneumovirus nucleocapsid protein based on insect-baculovirus system

The invention discloses a method for preparing human metapneumovirus nucleocapsid protein based on an insect-baculovirus system. Comprising the following steps: 1) constructing a recombinant vector with a human metapneumovirus nucleocapsid protein coding sequence: sequentially connecting a sequence for promoting secretory expression, the human metapneumovirus nucleocapsid protein coding sequence and a tag sequence from 5'to 3 'ends in the recombinant vector; 2) converting the recombinant vector with the human metapneumovirus nucleocapsid protein coding sequence constructed in the step 1) into a competent cell containing a baculovirus genome plasmid Bacmid to obtain a recombinant baculovirus genome plasmid; and 3) transfecting insect cells with the recombinant baculovirus genome plasmid obtained in the step 2), culturing and purifying to obtain the human metapneumovirus nucleocapsid protein. The invention provides the preparation method of the human metapneumovirus nucleocapsid protein, and a material support is provided for subsequent further research.
Owner:INST OF PATHOGEN BIOLOGY CHINESE ACADEMY OF MEDICAL SCI

Construction method and application of modified AAV-8 serotype for retina wide targeting and expression

The invention belongs to the technical field of gene engineering and biology, discloses a modified adeno-associated virus AAV-8 serotype for retina wide targeting and expression, and further relates to construction and application of the modified type. 10 amino acid sequences as shown in SEQ ID NO.3 are inserted between the 590th amino acid and the 591th amino acid of an AAV-8 serotype capsid protein sequence as shown in SEQ ID NO.2, the first, second and tenth amino acids are protected amino acids, and the third to ninth amino acids are amino acid sequences obtained by screening. The modified serotype disclosed by the invention is stronger in fluorescence effect after infection and can be obviously and intuitively observed, an exogenous gene can be widely and efficiently expressed in a specific targeted tissue retina whole region, and the expression efficiency is greatly improved under the condition of using the same virus amount. And compared with a wild serotype, the serotype has better and wider targeted tissue expression and less non-targeted tissue expression.
Owner:SHANGHAI OPHTHAL-BRIGHT BIOMEDICINE TECH

Recombinant AAVS with improved tropism and specificity

PCT designated stage expiredWO2024238807A2VectorsViral antigen ingredientsBio distributionTropism
The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR VIII) and / or a peptide segment in variable region I (VR 1). The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapies targeted at a specific tissue.
Owner:AFFINIA THERAPEUTICS INC

Polypeptide for enhancing porcine epidemic diarrhea virus replication and application thereof

The invention relates to a bioengineering technology, and aims to provide a polypeptide for enhancing porcine epidemic diarrhea virus replication and application thereof. The polypeptide is a transmembrane polypeptide targeting a PEDV replication stage, and 58th arginine in a nucleocapsid N protein sequence of PEDV is used as a target; the polypeptide is named as R58-WT polypeptide, and the amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. According to the invention, a key site influencing virus replication in an N-terminal region of PEDV N protein is used as a new target spot, the polypeptide has a very significant promotion effect in PEDV infection model verification experiments of IPEC-J2, Vero and ST cells, and the problems of weak low-generation virulence, poor cell adaptability, difficulty in passage and the like in the process of rescuing PEDV low virulent strains can be perfectly solved.
Owner:ZHEJIANG UNIV